Welcome to our dedicated page for Vitrolife news (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife stock.
The VTRLY news page tracks company communications and market-facing updates related to Vitrolife AB (publ), a biotechnology group active in reproductive health. Investors can use this feed to follow how the Vitrolife Group reports on its regional and product group performance, as well as strategic and financing developments that may influence the underlying business.
Vitrolife AB (publ) regularly publishes interim reports that detail sales in local currencies across EMEA, Americas and APAC, and across its Consumables, Technologies and Genetics product groups. These reports discuss organic growth excluding discontinued business, currency effects on sales and margins, gross margin levels, EBITDA, operating cash flow and net income. News items linked to these reports often include conference call invitations, where management presents the results and answers questions from investors, analysts and financial media.
The news flow also covers strategic initiatives and organisational changes. For example, Vitrolife AB (publ) has announced that it became a leading investor in AutoIVF, an early-stage MedTech company focused on making IVF more accessible, affordable and efficient through its OvaReady™ technology. The company has also communicated changes to its Executive Management Team, including the introduction of a SVP Innovation role to oversee R&D, Strategy & Sustainability, Portfolio Lifecycle Management and Market Access.
Governance and capital structure events appear in the form of Annual General Meeting notices and reports, which describe proposed and approved dividends, Board elections, auditor re-elections, share issue and share repurchase authorisations and share-based incentive programs. Financing news includes announcements such as the renewal and signing of a loan agreement comprising a term loan and revolving credit facility backed by Nordic banks.
By reviewing the VTRLY news feed, readers can follow how Vitrolife AB (publ) communicates on financial performance, IVF-related strategic investments, executive appointments, governance decisions and loan facilities. This makes the page a useful reference for anyone monitoring the company’s publicly disclosed developments over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vitrolife AB reported strong financial performance for the first quarter of 2023. Sales reached SEK 854 million, marking a 14% increase, with local currency growth of 9% excluding discontinued operations. Consumables sales rose by 12%, Technologies by 7%, and Genetic Services by 7% as well. All regions showed growth: APAC 23%, Americas 6%, and EMEA 1%. The gross margin improved to 56.8%, while EBITDA was SEK 262 million, reflecting a margin of 33.0%. Net income increased to SEK 99 million, resulting in SEK 0.74 per share, up 23%. Following the reporting period, Jón Sigurdsson became interim CEO, with new CEO Bronwyn Brophy set to join on August 1, 2023.
Vitrolife AB is scheduled to hold a conference call on April 21, 2023, at 10:00 a.m. CET, to discuss its interim report for Q1 2023. The call will be conducted in English, and registration is required to participate. During the call, key executives, including Jón Sigurdsson, Interim CEO, and Patrik Tolf, CFO, will be present. The interim report will be released at 8:00 CET on the same day, and presentation materials will be available on the company website prior to the call. A recorded version of the call will be accessible for seven days post-event.
Summary not available.
Vitrolife AB invites shareholders to its Annual General Meeting on April 27, 2023, at 4:00 PM in Gothenburg, Sweden. Shareholders must notify attendance by April 21, 2023, and be recorded in the share register by April 19, 2023. Key proposals include a dividend of SEK 0.85 per share, re-election of the Board members, and authorization for the Board to issue new shares. The total remuneration proposed for Board members is SEK 3,600,000, unchanged from last year. Other agenda items include amendments to facilitate postal voting and acquisition of the company's own shares.
Vitrolife AB reported strong financial results for Q4 and the full year 2022. Sales surged to SEK 855 million, a 66% increase driven by organic growth of 11%, acquired growth of 37%, and a currency effect of 18%. EBITDA reached SEK 273 million with a margin of 31.9%. For the full year, sales totaled SEK 3,234 million, up 92%, with EBITDA improving to SEK 1,050 million. The company announced the appointment of Bronwyn Brophy as new CEO starting August 2023, with an interim CEO from April 2023. Additionally, a proposed dividend of SEK 0.85 per share was announced.
Bronwyn Brophy has been appointed as the new CEO of Vitrolife (OTC-PINK:VTRLY), starting August 1, 2023. Brophy brings substantial leadership experience from previous roles at Thermo Fisher Scientific, Medtronic, and Johnson & Johnson. She will replace Thomas Axelsson, who will step down on March 31, 2023, with Jón Sigurdsson serving as interim CEO until Brophy's arrival. The board expects Brophy's experience will drive growth and enhance shareholder value. Sigurdsson praised her international experience as vital for the company’s future.